Literature DB >> 30601366

Measurement of Microvascular Function in Pediatric Inflammatory Bowel Disease.

Rebecca Winderman1, Simon S Rabinowitz, Katherine Vaidy, Steven M Schwarz.   

Abstract

BACKGROUND AND AIMS: Altered vascular flow is known to both play a role in the pathogenesis and influence the severity of inflammatory bowel disease (IBD). This phenomenon has been described in other systemic conditions and contributes to disease progression by facilitating inflammation and thrombosis. Microvascular dysfunction may represent an early sign of generalized vascular disease (VD). It manifests by failure to achieve a normal response of vasodilation and increased blood flow following a period of vaso-occlusion. Although thromboembolic complications are well described in IBD, their pathogenesis is not fully understood. This study sought to assess microvascular responsiveness in pediatric subjects with IBD, by recording postocclusion peripheral arterial pulsatile volume changes. PATIENTS AND METHODS: A total of 32 pediatric subjects were studied, including 16 with IBD and 16 age-matched controls. All patients with IBD were in clinical remission, and none had known VD. Vascular reactivity was evaluated using the Itamar Medical EndoPAT2000, a noninvasive device utilizing plethysmography to measure microvascular flow. Results were reported as the reactive hyperemia index (RHI), indicating post- to preocclusion pulsatile volume changes.
RESULTS: Baseline characteristics, including body mass index, plasma lipid levels, hemoglobin, and serum albumin, were similar in both study groups. All patients with IBD were in clinical remission, assessed by standard disease activity scoring methods. Measurements of microvascular function indicated patients with IBD exhibited a mean RHI both within the range associated with VD risk in adults (≤1.67) and significantly lower than that in controls (IBD vs control = 1.66 vs 2.02, P = 0.036).
CONCLUSIONS: Microvascular plethysmography is a safe and noninvasive method for assessing microvascular function in children with IBD. Patients with IBD in clinical remission demonstrate an attenuated, postocclusion microvascular hyperemic response, compared with the normal response in controls. These findings suggest pediatric IBD subjects with a mean RHI within the VD "at risk" range should be monitored for thromboembolic phenomena. Further studies in a larger patient population and over longer periods should be conducted to validate our findings and to determine the importance of these measurements in guiding IBD management.

Entities:  

Year:  2019        PMID: 30601366     DOI: 10.1097/MPG.0000000000002252

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  4 in total

Review 1.  Endothelial Dysfunction and Arterial Stiffness in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Hao Wu; Meihua Xu; Hong Hao; Michael A Hill; Canxia Xu; Zhenguo Liu
Journal:  J Clin Med       Date:  2022-06-02       Impact factor: 4.964

2.  Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS).

Authors:  Carmen Scheibenbogen; Franziska Sotzny; Milan Haffke; Helma Freitag; Gordon Rudolf; Martina Seifert; Wolfram Doehner; Nadja Scherbakov; Leif Hanitsch; Kirsten Wittke; Sandra Bauer; Frank Konietschke; Friedemann Paul; Judith Bellmann-Strobl; Claudia Kedor
Journal:  J Transl Med       Date:  2022-03-22       Impact factor: 5.531

3.  Plasma asprosin, CCDC80 and ANGPTL4 levels are associated with metabolic and cardiovascular risk in patients with inflammatory bowel disease.

Authors:  Hao-Hua Wang; Wan-Ying Luo; Min Lin; Xiao-Jing Li; Guang-Da Xiang; Silvia D Triganti
Journal:  Physiol Res       Date:  2021-03-08       Impact factor: 1.881

Review 4.  The risk of cardiovascular complications in inflammatory bowel disease.

Authors:  Piotr Czubkowski; Marcin Osiecki; Edyta Szymańska; Jarosław Kierkuś
Journal:  Clin Exp Med       Date:  2020-08-12       Impact factor: 3.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.